ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/sarcoma
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Sarcoma, Endocrine, and Rare Cancers / Sarcoma
25
trial(s) found.
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06789172
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (
INVOKE
)
anti-PD-1 monoclonal antibody
prostaglandin EP2/EP4/DP1 receptor inhibitor
Colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Sarcoma
Solid tumour
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
WA
6009 - Nedlands - Linear Clinical Research
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06127407
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen (
CHONQUER
)
IDH1 R132 inhibitor
placebo
Chondrosarcoma
NOT Dedifferentiated chondrosarcoma
NOT Mesenchymal chondrosarcoma
NOT Myxoid chondrosarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05619913
Advanced
Phase 2
Recruiting
The
EPOCH
Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma
anti-PD-1 monoclonal antibody
macrocyclic ketone analogue
Ovarian carcinosarcoma
Uterine carcinosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05504291
Advanced
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
Retinoblastoma
WA
6009 - Perth - Perth Children's Hospital
NCT05304585
Advanced
Phase 3
Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (
ARST2032
)
Cyclophosphamide
Dactinomycin
Radiotherapy
Vincristine
alkylating agent
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
vinca alkaloid
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05286801
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (
NCI-2022-01992
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
Atypical teratoid rhabdoid tumour
Carcinoma
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT04950075
Advanced
Phase 2
Recruiting
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma (
ChonDRAgon
)
anti-DR5 agonistic antibody
placebo
Chondrosarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04870944
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Lymphoma
Osteosarcoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
NCT04322318
Advanced
Phase 2
Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (
AREN1921
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Radiotherapy
Topotecan
Vincristine
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
Wilms tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04185883
Advanced
Phase 1
Recruiting
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
Sarcoma
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (TERMINATED)
NCT04140526
Advanced
Phase 1 / Phase 2
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (
PRESERVE-001
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenoid cystic carcinoma
Breast cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT04031677
Curative
Phase 3
Recruiting
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) (
STRASS2
)
Dacarbazine
Doxorubicin
Epirubicin
Ifosfamide
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
Leiomyosarcoma
Liposarcoma
Peritoneal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000554561
Curative
Recruiting
Prospective Study Evaluating The Treatment Outcomes For Localised Recurrent, Resectable Retroperitoneal Liposarcoma in adults (
ReLaPSe
)
Radiotherapy
cancer therapy
Liposarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12624000532505
Advanced
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621000639820
Advanced
Phase 2
Recruiting
The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (
PARAGON-II
) .
Alpelisib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Letrozole
PI3K alpha inhibitor
Ribociclib
aromatase inhibitor
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,PI3Kalpha-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
oestrogen receptor-targeting therapy
Carcinoma
Endometrial cancer
Endometrial stromal sarcoma
Low-grade serous ovarian cancer
Ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Uterine leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2485 - Tweed Heads - The Tweed Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12618001825246
Advanced
Phase 2 / Phase 3
Recruiting
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma (
2014-000259-99
)
Carboplatin
Cyclophosphamide
Docetaxel
Etoposide
Gemcitabine
Ifosfamide
Irinotecan
Lenvatinib
Temozolomide
Topotecan
VEGF inhibitor
alkylating agent
antimetabolite
cancer therapy
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
Ewing sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06058793
Advanced
Phase 3
Not recruiting
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma (
1403-0019
)
MDM2 inhibitor
Liposarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05605522
Advanced
Phase 1
Active not recruiting
A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours (
FPI-2059-101
)
radioconjugate,NTSR1-targeting
Colorectal cancer
Ewing sarcoma
Gastric cancer
Head and neck squamous cell carcinoma
Pancreatic adenocarcinoma
Prostate cancer
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT05440786
Advanced
Phase 2
Active not recruiting
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma
CDK4/6 inhibitor
alkylating agent
topoisomerase inhibitor
Ewing sarcoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05349643
Advanced
Phase 2
Completed
A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor (
AMB-051-07
)
anti-CSF1R monoclonal antibody
Tenosynovial giant cell tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05269355
Advanced
Phase 2 / Phase 3
Terminated
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma (
SUNRISELMS
)
BMI-1 inhibitor
Leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05228015
Advanced
Phase 1
Terminated
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors (
IK930-001
)
YAP-TEAD inhibitor
Epithelioid haemangioendothelioma
Mesothelioma
Pleural mesothelioma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT05218499
Advanced
Phase 2 / Phase 3
Active not recruiting
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma (
1403-0008
)
MDM2 inhibitor
anthracycline
Liposarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Glandore - Ashford Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (17)
Active not recruiting (3)
Terminated (2)
Not yet recruiting (1)
Not recruiting (1)
Completed (1)
Recruitment Country and State
NSW (21)
VIC (15)
QLD (14)
WA (10)
SA (9)
NZ (3)
TAS (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (3)
Phase 2 (7)
Phase 2 / Phase 3 (3)
Phase 3 (5)
Trial Type
Advanced (23)
Curative (2)
Cancer Therapy Class
PD-1/PD-L1
20%
PD-1
16%
CDK4
12%
CDK6
12%
PD-L1
8%
EGFR
8%
VEGF
8%
MDM2
8%
prostaglandin DP1 receptor
4%
prostaglandin EP2 receptor
4%
prostaglandin EP4 receptor
4%
B7H3
4%
IDH1
4%
IDH1 R132
4%
TIGIT
4%
DR5
4%
FACT complex
4%
ERBB2
4%
HRAS G12C
4%
KRAS
4%
KRAS G12C
4%
MEK
4%
NRAS G12C
4%
SHP2
4%
mTOR
4%
mTORC1
4%
CTLA4
4%
FGFR
4%
FGFR1
4%
FGFR1/2/3
4%
FGFR2
4%
FGFR3
4%
FGFR4
4%
KIT
4%
PDGFR
4%
RET
4%
VEGFR
4%
PI3Kalpha
4%
oestrogen axis
4%
NTSR1
4%
CSF1R
4%
BMI-1
4%
YAP-TEAD
4%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (9)
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
4102 - Woolloongabba - Princess Alexandra Hospital (7)
2031 - Randwick - Prince of Wales Hospital (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
2031 - Randwick - Sydney Children's Hospital (4)
6009 - Perth - Perth Children's Hospital (3)
2145 - Westmead - The Children's Hospital at Westmead (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
5042 - Bedford Park - Flinders Medical Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
NZ.1023 - Grafton - Starship Children's Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
3052 - Parkville - Royal Children's Hospital Melbourne (2)
4101 - South Brisbane - Queensland Children's Hospital (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (1)
6009 - Nedlands - Linear Clinical Research (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
4215 - Southport - Tasman Oncology (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
Cancer Type
Cancer
Sarcoma
Solid tumour
Soft tissue sarcoma
Bone cancer
Colorectal cancer
Gastrointestinal cancer
Gynaecological cancer
Head and neck cancer
Lower gastrointestinal cancer
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Thoracic cancer
Upper gastrointestinal cancer
Liposarcoma
Ewing family of tumours
Gastric cancer
Gastroesophageal cancer
Lung cancer
Male genital cancers
Prostate cancer
Respiratory tract cancer
Urogenital cancer
Carcinoma
Ewing sarcoma
Primitive neuroectodermal tumour
Cervical cancer
Clear cell renal cell carcinoma
HPV-related cancer
HPV16-positive cancer
Kidney cancer
Melanoma
Viral-related cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Endometrial cancer
Epithelial Ovarian Cancer
Ovarian adenocarcinoma
Leiomyosarcoma
Bladder cancer
Breast cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Oesophageal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Neuroendocrine carcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Chondrosarcoma
Central nervous system cancer
Neurological cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Carcinosarcoma
Ovarian carcinosarcoma
Uterine carcinosarcoma
Retinoblastoma
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Atypical teratoid rhabdoid tumour
Central nervous system primitive neuroectodermal tumour
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Diffuse intrinsic pontine glioma
Glioma
H3K27M-mutant glioma
Haematological malignancy
High-grade glioma
Lymphoma
Malignant glioma
Osteosarcoma
Wilms tumour
Adenoid cystic carcinoma
Cancer Solid tumour Carcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Salivary gland cancer
Urothelial carcinoma
Peritoneal cancer
Endometrial stromal sarcoma
Fallopian tube cancer
Low-grade serous ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Primary fallopian tube serous carcinoma
Sex cord-gonadal stromal tumour
Uterine leiomyosarcoma
Tenosynovial giant cell tumour
Epithelioid haemangioendothelioma
Mesothelioma
Pleural mesothelioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy